Torrent Pharmaceuticals Ltd Forensic Report - SOIC x StockScans Report

as of Jul 2026

Torrent Pharmaceuticals’ record is built on a disclosed and audited structure, with operating cash flow that has covered profit in every year since FY21 and a clean resolution of its USFDA facility clearances. Three things demand attention: the balance sheet is now dominated by goodwill and brands from the JB Pharma acquisition, borrowings have surged 5.6× to fund it, and reported profit has been repeatedly reshaped by exceptional items and tax-regime changes.

Key findings

  1. Goodwill and brands dominate the balance sheet after the JB Pharma acquisition Major - Goodwill impairment testing has been a Key Audit Matter, an area requiring the most auditor judgement, on both standalone and consolidated financial statements every year from FY2018-19 through FY2025-26. Management asserts that no reasonably possible change in key assumptions would cause the carrying amount to exceed the recoverable amount, despite a ₹439.02 crore impairment of a US subsidiary’s assets in FY2022 and an earlier impairment on the Bio-Pharm acquisition. The FY2025-26 consolidated goodwill impairment test uses a discount rate of 11% and a projected revenue growth rate of 5% to 18%.
  2. Borrowings surged 5.6× to ₹15,026 crore to fund the acquisition Major - Consolidated borrowings rose from ₹2,548 crore at March 2025 to ₹15,026 crore at March 2026, driven by the JB Pharma acquisition. The company allotted ₹10,990 crore of non-convertible secured debentures on 19 January 2026, with ₹10,760.74 crore secured by a first-ranking exclusive charge over Designated Account Assets and Specified Trademarks. Management stated net debt-to-EBITDA at 2.3× in the Q4 FY26 call, using a pro-forma full-year EBITDA for JB Pharma rather than actual consolidated EBITDA for the period.
  3. Exceptional items and tax changes have repeatedly reshaped reported profit Major - In FY2022, an exceptional charge of ₹485 crores for impairment of the US liquid facility drove consolidated PAT down to ₹777 crores. The FY2023 NCLT merger of Curatio triggered a reversal of deferred tax liability of ₹458.52 crores recorded as an exceptional item, and in FY2025 the company remeasured deferred tax balances upon opting for the Section 115BAA regime, crediting ₹150.63 crores to the standalone P&L. The consolidated deferred tax asset on subsidiary tax losses rose to ₹280.25 crores in FY2026, with realisation dependent on management’s future taxable income projections.
  4. Related-party dealings are dominated by trade with the US subsidiary Minor - Standalone sales of finished goods to wholly-owned US subsidiary Torrent Pharma Inc. were ₹1,141.01 crore in FY2018-19 and ₹1,046.74 crore in FY2020-21, with a Product Supply Agreement providing credit terms of 210 days. The Board obtained shareholder approval on 29 July 2025 to increase the limit for loans, guarantees, and investments from ₹10,000 crore to ₹26,000 crore to facilitate the JB Pharma acquisition. The company’s filings for every year from FY2018-19 to FY2025-26 state that no related party transactions were material under Regulation 23 of the Listing Regulations.
  5. The group maintains a layered structure of 18 subsidiaries with cross-holdings Minor - As of 31 March 2026, Torrent Pharmaceuticals has 18 subsidiaries, unchanged in count from FY25 despite the addition of JB Pharma and the removal of UNM Foundation. On 21 January 2026, the company acquired a 48.80% controlling stake in JB Pharma, becoming its Promoter. The company also made a 26% equity investment in Torrent Urja 27 Private Limited, which became an Associate Company.
  6. Two long-running US product-liability litigations and Indian tax disputes persist Minor - Two Multi-District Litigations for Valsartan and Losartan are pending against Torrent and other manufacturers in US district courts. The company states the financial effect is difficult to ascertain and carries product liability insurance it believes sufficient. Disputed indirect tax matters aggregated ₹91.11 crores as of 31 December 2025, and outstanding guarantees issued to third parties on behalf of wholly owned subsidiaries rose to ₹993.87 crores at 31 March 2026.
  7. USFDA facility clearances were fully resolved by FY26 Clean - Torrent’s Dahej and Indrad facilities were classified OAI and Warning Letter respectively by USFDA in FY2019, placing new US product approvals on hold. By FY26, the company received USFDA Establishment Inspection Reports for its Dahej plant and Vizag API plant, and all four plants manufacturing finished products for the US market have been cleared by the FDA. The company’s annual corporate governance reports for FY21 through FY26 each state that no penalties were imposed by SEBI or Stock Exchanges on capital-market matters during the preceding three years.
  8. Operating cash flow consistently covers profit, but capital allocation is shifting Clean - Cumulative CFO of ₹15,050 crore exceeded cumulative PAT of ₹8,979 crore over FY21-FY26, with annual CFO/PAT ratios ranging from 1.35x to 2.32x. Total dividend outgo increased from ₹592 crore in FY21 to ₹1,286 crore in FY26, and the Dividend Distribution Policy was revised to target 50% of annual consolidated PAT, excluding non-cash acquisition charges. ROCE declined from 27.10% in FY25 to 13.91% in FY26, while interest coverage stood at 8.46x on consolidated borrowings of ₹15,026 crore.

What to watch

Bottom line: This is a disclosed and audited record with genuine cash generation and a clean regulatory resolution on the manufacturing front. The character of the risk has shifted decisively to the balance sheet: the JB Pharma acquisition has loaded goodwill, brands, and debt onto the books at a scale that will take years to work through reported earnings. Watch the purchase price allocation, the NCLT amalgamation ruling, and the refinancing of the ₹10,760.74 crore NCDs secured by a first-ranking exclusive charge over Designated Account Assets and Specified Trademarks.